Antagonists of cxcr3-binding cxc chemokines
US7541435B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 3, 2003 |
| Grant date | Jun 2, 2009 |
| Priority date | — |
| Expiry date | Feb 22, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel antagonists of CXCR3-binding CXC chemokines, and in particular of human CXCL11, can be obtained by generating mutants of such chemokines in which the binding to glycosaminoglycans (GAGs) is impaired due to non-conservative substitutions of amino acids involved in this interaction. Compounds prepared in accordance with the present invention can be used to block the activity of CXCR3-binding CXC chemokines on CXCR3-expressing cells, thereby providing therapeutic compositions for use in the treatment or prevention of diseases related to excessive activated T cells migration, such as graft rejection and autoimmune diseases, and of diseases needing an increase of vascularization, such as ischemic heart disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.